Cerity Partners’s Quince Therapeutics QNCX Stock Holding History

Cerity Partners’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-949	Closed	-$636K	–	3372
2025 Q4	$636K	Buy	+949	New	+$478K	﹤0.01%	1958

Other funds holding QNCX

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Cerity Partners's QNCX Position: Q1 2026 in Review

Cerity Partners sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 949 shares — an estimated $636K sold.

Cerity Partners first reported a position in QNCX in Q4 2025 and held it in 1 quarter. The position peaked at $636K in Q4 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

Cerity Partners reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
Cerity Partners sold 949 Quince Therapeutics shares in Q1 2026, an estimated $636K.
Cerity Partners first reported a position in Quince Therapeutics in Q4 2025 and held it in 1 quarter.
Cerity Partners's Quince Therapeutics position peaked at $636K in Q4 2025.
43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.